Published in J Virol on July 25, 2007
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol (2008) 1.73
HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response. AIDS (2009) 1.11
Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays. Antimicrob Agents Chemother (2009) 1.04
HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners. Retrovirology (2013) 0.90
Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. Virology (2009) 0.87
Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers. AIDS Res Hum Retroviruses (2012) 0.84
In-depth characterization of viral isolates from plasma and cells compared with plasma circulating quasispecies in early HIV-1 infection. PLoS One (2012) 0.80
Low-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP elite controller. PLoS One (2012) 0.79
Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristics. J Virol Methods (2015) 0.78
HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype. AIDS (2013) 0.78
Maternal Neutralization-Resistant Virus Variants Do Not Predict Infant HIV Infection Risk. MBio (2016) 0.76
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell (1989) 9.66
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33
GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol (2006) 5.28
Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol (2000) 3.83
Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol (2006) 3.26
Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis (1998) 2.96
Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories. J Clin Microbiol (1992) 2.95
Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol (2004) 2.91
Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol (1999) 2.90
Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J Virol (1992) 2.88
Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol (1997) 2.72
Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol (2006) 2.70
Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis (2004) 2.47
Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology (1999) 2.27
CD4+ lymphocyte count in African patients co-infected with HIV and tuberculosis. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 2.23
Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest (2000) 2.21
Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol (2006) 2.00
Polymorphic human gene(s) determines differential susceptibility of CD4 lymphocytes to infection by certain HIV-1 isolates. Virology (1991) 1.65
Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updat (2002) 1.54
Procedures for reliable estimation of viral fitness from time-series data. Proc Biol Sci (2002) 1.46
Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection. J Virol (2003) 1.44
Effect of different donor cells on human immunodeficiency virus type 1 replication and selection in vitro. J Virol (1995) 1.35
Functional characterization of the V1V2 region of human immunodeficiency virus type 1. Virology (1996) 1.28
Quantification of genital human immunodeficiency virus type 1 (HIV-1) DNA in specimens from women with low plasma HIV-1 RNA levels typical of HIV-1 nontransmitters. J Clin Microbiol (2006) 1.17
Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression. AIDS (2002) 1.10
Fitness landscape of human immunodeficiency virus type 1 protease quasispecies. J Virol (2006) 1.06
Isolation, propagation, and titration of human immunodeficiency virus type 1 from peripheral blood of infected individuals. Methods Mol Biol (2005) 0.96
Investigation of population diversity of human immunodeficiency virus type 1 in vivo by nucleotide sequencing and length polymorphism analysis of the V1/V2 hypervariable region of env. J Gen Virol (1997) 0.89
Simian immunodeficiency virus variants that differ in pathogenicity differ in fitness under rapid cell turnover conditions. J Virol (2005) 0.89
Analysis of length variation in the V1-V2 region of env in nonsubtype B HIV type 1 from Uganda. AIDS Res Hum Retroviruses (2002) 0.80
Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci U S A (2005) 6.85
Visualization of the intracellular behavior of HIV in living cells. J Cell Biol (2002) 6.59
HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe (2008) 5.90
Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol (2004) 4.76
HIV vaccine research: the way forward. Science (2008) 3.86
HIV/AIDS in women: an expanding epidemic. Science (2005) 3.68
Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog (2006) 3.67
Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J Virol (2004) 3.54
Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial. AIDS (2008) 3.42
HIV-1 disease progression in breast-feeding and formula-feeding mothers: a prospective 2-year comparison of T cell subsets, HIV-1 RNA levels, and mortality. J Infect Dis (2006) 3.09
Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol (2006) 2.95
HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis (2007) 2.87
Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses (2010) 2.86
Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe (2008) 2.85
The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell Host Microbe (2012) 2.79
Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells. PLoS Pathog (2007) 2.75
HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses (2002) 2.68
Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis (2006) 2.65
Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis (2004) 2.47
Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis (2004) 2.45
Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS (2007) 2.44
Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J Virol (2006) 2.40
Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog (2007) 2.38
Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr (2007) 2.34
Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol (2004) 2.33
Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected african children. Pediatr Infect Dis J (2004) 2.30
Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr (2009) 2.26
Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women. J Infect Dis (2009) 2.24
Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol (2009) 2.16
Retroviral infection of non-dividing cells: old and new perspectives. Virology (2006) 2.11
Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol (2012) 2.10
Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis (2003) 2.10
The cell cycle independence of HIV infections is not determined by known karyophilic viral elements. PLoS Pathog (2005) 2.02
HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS (2007) 1.99
Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J Virol (2006) 1.98
Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol (2003) 1.96
Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. J Virol (2002) 1.91
Acute cytomegalovirus infection in Kenyan HIV-infected infants. AIDS (2009) 1.87
Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86
High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans. Curr Biol (2006) 1.85
Validation of performance of the gen-probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples. J Clin Microbiol (2002) 1.82
Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol (2005) 1.77
Restriction of an extinct retrovirus by the human TRIM5alpha antiviral protein. Science (2007) 1.76
The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis (2007) 1.75
Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis (2004) 1.74
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol (2008) 1.73
Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol (2003) 1.72
HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog (2012) 1.70
Association between cervical shedding of herpes simplex virus and HIV-1. AIDS (2002) 1.64
Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. AIDS (2012) 1.64
Cyclophilin A interacts with diverse lentiviral capsids. Retrovirology (2006) 1.63
Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. J Infect Dis (2004) 1.61
Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. J Virol (2010) 1.61
Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med (2008) 1.60
Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals. PLoS Pathog (2007) 1.60
HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission. J Infect Dis (2009) 1.57
HIV acquisition during pregnancy and postpartum is associated with genital infections and partnership characteristics. AIDS (2015) 1.55
Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. AIDS (2004) 1.55
Positive selection and increased antiviral activity associated with the PARP-containing isoform of human zinc-finger antiviral protein. PLoS Genet (2008) 1.52
Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Curr HIV Res (2003) 1.52
A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med (2011) 1.51
Rapid detection of HIV-1 proviral DNA for early infant diagnosis using recombinase polymerase amplification. MBio (2013) 1.50
No evidence for rapid subtype C spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate. AIDS Res Hum Retroviruses (2005) 1.47
Human Trim5α has additional activities that are uncoupled from retroviral capsid recognition. Virology (2010) 1.40
Paleovirology - ghosts and gifts of viruses past. Curr Opin Virol (2011) 1.37
Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis (2003) 1.36
HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS (2008) 1.36
Dendritic cell-mediated viral transfer to T cells is required for human immunodeficiency virus type 1 persistence in the face of rapid cell turnover. J Virol (2002) 1.34
Examination of a second region of the HIV type 1 genome reveals additional cases of superinfection. AIDS Res Hum Retroviruses (2008) 1.34
The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J Virol (2010) 1.34
Basic statistical considerations in virological experiments. J Virol (2005) 1.32
Cellular restriction targeting viral capsids perturbs human immunodeficiency virus type 1 infection of nondividing cells. J Virol (2009) 1.32
The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS (2004) 1.32
Cyclic shedding of HIV-1 RNA in cervical secretions during the menstrual cycle. J Infect Dis (2004) 1.31
Evolution-guided identification of antiviral specificity determinants in the broadly acting interferon-induced innate immunity factor MxA. Cell Host Microbe (2012) 1.29
Longitudinal assessment of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon responses during the first year of life in HIV-1-infected infants. J Virol (2005) 1.28
Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS (2007) 1.28
Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proc Natl Acad Sci U S A (2002) 1.27
Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. AIDS (2005) 1.27
The host restriction factor APOBEC3G and retroviral Vif protein coevolve due to ongoing genetic conflict. Cell Host Microbe (2012) 1.26
Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J Virol (2009) 1.24
Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis (2010) 1.22
HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog (2013) 1.21
Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Res Hum Retroviruses (2006) 1.21
Convergence and divergence in the evolution of the APOBEC3G-Vif interaction reveal ancient origins of simian immunodeficiency viruses. PLoS Pathog (2013) 1.19
Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr HIV Res (2007) 1.19
Virus load during primary Human Immunodeficiency Virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women. Clin Infect Dis (2002) 1.19
Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS (2004) 1.19
Quantification of genital human immunodeficiency virus type 1 (HIV-1) DNA in specimens from women with low plasma HIV-1 RNA levels typical of HIV-1 nontransmitters. J Clin Microbiol (2006) 1.17
A putative thiamine transport protein is a receptor for feline leukemia virus subgroup A. J Virol (2006) 1.17